wire - news in brief




Page not found (Error 404)




Health - Dec 6
Taking cholesterol-lowering drugs, or statins, as a preventive measure can reduce the risk of cardiovascular disease. A study by the University of Zurich now shows that this measure is recommended too often, as current guidelines fail to take into account the risks of side effects. Even healthy people who don't suffer from a cardiovascular disease are prescribed cholesterol-lowering drugs, known as statins, if they meet certain risk criteria.
Life Sciences - Dec 5

In a study published in Neuron, researchers have demonstrated how functional ultrasound imaging can yield high-resolution, unbiased, brain-wide activity maps of behaving mice.

Business - Dec 4
Business

Farmers in developing countries often rely heavily on their yearly harvest to feed their families. A bad crop can have severe consequences for their livelihood.


Category



Results 1 - 50 of 366.
1 2 3 4 5 8 Next »


Academic Rankings - 08:00

Pharmacology - Health - 10.12.2018
Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
ReSET-O TM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-a

Innovation / Technology - 10.12.2018

Health - Pharmacology - 08.12.2018
Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
  Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy

Pharmacology - Health - 07.12.2018
FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with n

Physics - Administration - 06.12.2018
EU grants 14 million to Swiss Researchers
Fuelling the next quantum revolution with the research project HERO An ERC Grant is the most prestigious award for excellent European research projects. A team with three researchers from the ETH Domain had also applied for such a grant. Today, Gabriel Aeppli from the Paul Scherrer Institute PSI, Henrik Rønnow from the Swiss Federal Institute of Technology Lausanne EPFL and Nicola Spaldin from ETH Zurich, together with their colleague Alexander Balatsky from Nordita, Stockholm University, received the contract signed by the EU confirming the extraordinary 14 million euro funding.

Environment - Administration - 06.12.2018
Four researchers from the University of Bern are awarded EU research prizes
Four researchers from the University of Bern are awarded EU research prizes
Four of the highly-regarded "ERC Consolidator Grants", the research prizes of the European Research Council (ERC), have been awarded to researchers at the University of Bern.

Transport - 05.12.2018
EPFL part of Europe's largest research initiative on urban mobility
The MOBiLus consortium, made up of nearly 50 organizations including EPFL, has just won major EU financing to study new approaches to urban transportation.

Health - Pharmacology - 05.12.2018
Roche’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Her

Pharmacology - Health - 05.12.2018
FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizum

Environment - 05.12.2018
Bringing La Buvette d'Evian back to life
Bringing La Buvette d'Evian back to life
In a new book, EPFL researchers trace the history of La Buvette d'Evian - a former lakeside refreshment area that is also an icon of modern architecture. With some light renovation work, La Buvette could reinvigorate the entire region. The book launch will take place on 6 December at EPFL. For over 40 years, tourists and people with kidney ailments came to La Buvette d'Evian for the healing properties of the region's water.

Astronomy / Space Science - 04.12.2018

Pharmacology - Health - 04.12.2018
Novartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head data
PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients ,   Ligelizumab (QGE031), a monoclonal antibody, is being deve

Pharmacology - Health - 04.12.2018
New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated res

Pharmacology - Health - 03.12.2018
Roche’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-pati

Pharmacology - Health - 03.12.2018
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide a promising new treatment option at first relapse Results from the GO29365 study, the first and only randomised study to suggest a survival benefit for patients not eligible for a haematopoie

Materials Science - 03.12.2018

Pharmacology - Health - 03.12.2018
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
The AVXS-101, now known as ZOLGENSMA (onasemnogene abeparvovec-xxxx) , filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative improvement in achievement of developmental milestones compared to the natural history of SMA Type 1   SMA Type 1 is a progressive neuromuscular disease and the leading cause of genetic mortality in infants globally   ZOLGENSMA represents the first in a propr

Health - Pharmacology - 02.12.2018
Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies
Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs.

Health - Pharmacology - 01.12.2018
Novartis announces longer-term analyses from pivotal Kymriah trials that showed durable responses are maintained in patients with advanced blood cancers
In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of

Pharmacology - Health - 01.12.2018
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients Crizanlizumab, a monthly infusion

Computer Science / Telecom - Careers / Employment - 30.11.2018
EPFL delivers Switzerland's first Certificates of Open Studies
EPFL delivers Switzerland's first Certificates of Open Studies
Last fall, EPFL introduced a new continuing education program whereby participants earn a Certificate of Open Studies (COS) - the only one of its kind in Switzerland. The first COSs were handed out at a ceremony this past Thursday. Switzerland's very first Certificates of Open Studies (COSs) were handed out this past Thursday at a ceremony at EPFL.

Administration - Agronomy / Food Science - 30.11.2018

Physics - Careers / Employment - 30.11.2018
Ten projects awarded
ETH researchers had excellent results in the issuing of ERC grants: they were able to win 10 Consolidator Grants in the amount of 24 million Swiss francs for their research. Researchers from ETH Zurich have never before been able to win so many ERC Consolidator Grants in one round as they managed to this time.

Pharmacology - Health - 29.11.2018
Novartis announces EU approval of Gilenya for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-f

Innovation / Technology - 28.11.2018
Start-up Switzerland in numbers
Where does Switzerland as a start-up location stand in international comparison? How has it developed? What are the strengths and weaknesses' Now, we have data-based answers to these questions.

Life Sciences - Health - 23.11.2018
Rescue machinery prevents cellular suicide
Rescue machinery prevents cellular suicide
In a new study published in Science a team led by Prof. Petr Broz from the Department of Biochemistry identify a new mechanism to control immune cell death associated with inflammatory diseases, including sepsis, inflammatory bowel disease (IBD), and arthritis.

Health - Pharmacology - 23.11.2018
Novartis announces landmark EU approval for one-time gene therapy Luxturna to restore vision in people with rare inherited retinal disease
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65 g

Earth Sciences - 22.11.2018

Materials Science - Veterinary Science - 21.11.2018
Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for intensive induction che

Computer Science / Telecom - Transport - 20.11.2018
Industrial coatings: the next generation
Industrial coatings: the next generation
Industry representatives met at Empa's Thun campus last week to get information on the latest high-tech trends in industrial coatings. The partnership with the Hightech Zentrum Aargau strengthens the transfer of knowledge from research to companies. The joint technology briefing of Empa and the Hightech Zentrum Aargau on 14 November in Thun was fully booked with 80 participants.

Health - Business / Economics - 20.11.2018

Pharmacology - Health - 20.11.2018
Sandoz and Pear Therapeutics announce launch of reSET for treatment of patients with Substance Use Disorder
ReSET is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of abus

Politics - 19.11.2018
Addressing the Territorial Dimensions in Party-based Populism
Parution d'un numéro spécial de la revue Comparative European Politics consacré aux partis régionalistes populistes et édité par Reinhard Heinisch (Universität Salzburg), Emanuele Massetti (University of Surrey) et Oscar Mazzoleni (Université de Lausanne).

Health - Pharmacology - 19.11.2018
Fexinidazole - First All-Oral Treatment for Sleeping Sickness Approved
Fexinidazole - First All-Oral Treatment for Sleeping Sickness Approved
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness.

Life Sciences - 19.11.2018
Precise synaptic organization of a memory network
Precise synaptic organization of a memory network
In order to examine how synaptic inputs to individual neurons are organized in a distributed memory network, researchers from the Friedrich group performed electrophysiological recordings in the zebrafish homolog of the olfactory cortex. They found that large excitatory inputs were paired with large inhibitory inputs, which may seem counterintuitive because inhibition cancels excitation.

Event - Politics - 17.11.2018

Pharmacology - Health - 16.11.2018
FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation   Approval based on compelling benefit established through complete response rates among SAA patients when Promacta is added to standard immunosuppressive therapy relative to historic information on that therapy alone   Promacta is the first new treatment in decades fo
1 2 3 4 5 8 Next »